<unk>  (TP-434, Xerava) is a synthetic halogenated tetracycline class antibiotic in development by Tetraphase Pharmaceuticals. It is closely related to tigecycline. It has a broad spectrum of activity including many multi-drug resistant strains of bacteria. Phase III studies in complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI) were recently completed with mixed results.<unk>  has been granted fast track designation by the FDA.
Eravacycline
Doxycycline
Sarecycline
Oxytetracycline
Teicoplanin
Omadacycline
Chlortetracycline
Rifampicin